Brief: Spago Nanomedical To Report Data From Phase I Part Of Tumorad-01 Study Later In H1

Spago Nanomedical AB (publ)

10/01/2024 07:13

Jan 10 (Reuters) - Spago Nanomedical AB (publ)  SPAGO.ST :
    * PROCEEDS TO NEXT DOSE LEVEL IN PHASE I/IIA STUDY TUMORAD-01
    * INITIAL DATA FROM PHASE I PART OF STUDY IS EXPECTED TO BE REPORTED LATER IN FIRST HALF OF
2024

Source text for Eikon:  ID:nMFN48tM14 
Further company coverage:  SPAGO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))